Nutrition, Psychology & Holistic IBD Care
Module Overview
Nutritional assessment and interventions (exclusive enteral nutrition, dietary therapies), psychological support, shared decision-making, and patient self-management strategies.
Benchmark Source: ECCO Nutrition & Psychosocial Modules + Mount Sinai Multidisciplinary Track
Learning Objectives
Perform nutritional risk screening and initiate appropriate dietary interventions
Discuss evidence for exclusive enteral nutrition, CD-TREAT, and Mediterranean diet
Screen for and address anxiety, depression, and fatigue in IBD
Apply shared decision-making frameworks and health literacy principles
Teaching Sessions
Nutritional Assessment & Interventions in IBD
Comprehensive nutritional care: screening, micronutrients, anemia, sarcopenia, and Saudi-context dietary considerations.
1Malnutrition Screening & Assessment
Malnutrition affects 20–85% of IBD patients depending on setting (outpatient clinic to hospitalized). Use validated tools: MUST (Malnutrition Universal Screening Tool)—BMI, unintentional weight loss, acute disease effect; NRS-2002 for inpatients; SaskIBD-NR for IBD-specific screening. Full assessment adds anthropometry (mid-upper arm circumference, triceps skinfold), body composition (bioimpedance, DEXA for sarcopenia detection—psoas muscle index on cross-sectional imaging is now standard), handgrip strength (dynamometry), and biochemistry (albumin, prealbumin, CRP-corrected nutritional indices, micronutrient panel). Sarcopenia (loss of muscle mass and function) is present in 40–60% of IBD patients even without weight loss—it predicts surgical complications, infections, biologic primary non-response, and mortality. Saudi context: high rates of vitamin D deficiency even in the general population (>50%), compounded in IBD; Hajj/Umrah fasting, Ramadan, cultural food preferences (carb-heavy, low-fiber in Gulf diet) all influence nutritional patterns—tailor advice accordingly.
Sarcopenia on CT psoas index is a better predictor of biologic failure and post-surgical complications than albumin or BMI. Start measuring it—you already have the scans.
- Screen every IBD clinic visit with MUST (<2 minutes)
- Sarcopenia in 40–60% even without weight loss
- Psoas muscle index on CT = prognostic marker
- Vitamin D deficiency prevalent in Saudi population baseline
- Handgrip dynamometry = cheap, validated functional measure
2Micronutrient Deficiencies & Repletion
Screen at baseline and at least annually: iron studies (ferritin, TSAT), B12, folate, vitamin D (25-OH), calcium, magnesium, zinc, vitamin A, thiamine (especially post-surgical), vitamin K (cholestasis or prolonged antibiotics). Iron deficiency is present in 45% of IBD patients; ferritin <30 ng/mL (or <100 with inflammation) with TSAT <20% = deficiency; treat IV iron when Hb <10 g/dL, intolerance to oral, active disease, or post-surgical (ferric carboxymaltose or iron isomaltoside—single 1000 mg infusion convenient); oral iron OK if mild deficiency and quiescent disease (ferrous sulfate 325 mg daily, not TID—higher doses induce hepcidin and paradoxically reduce absorption). B12 deficiency in terminal ileal disease or resection—IM 1000 mcg monthly or high-dose oral (1–2 mg daily) if mild. Vitamin D: target 25-OH >30 ng/mL; loading dose 50,000 IU weekly × 8 weeks, then 2000 IU daily maintenance. Zinc deficiency common in high-output fistulae/diarrhea—supplement 30 mg daily. Folate deficiency (especially on sulfasalazine or methotrexate)—5 mg weekly with MTX, 400 mcg daily otherwise. Selenium, copper: consider in TPN-dependent or short bowel patients.
Oral iron once daily beats TID: higher doses spike hepcidin, paradoxically reducing fractional absorption. One tablet with vitamin C at morning, on empty stomach, is the evidence-based protocol.
- Iron deficiency in 45%—IV iron if Hb <10, oral intolerance, or active disease
- B12 post-ileal resection = monthly IM 1000 mcg
- Vitamin D target >30 ng/mL; loading then maintenance
- Oral iron: single dose daily > TID (hepcidin biology)
- Zinc supplementation for high-output fistulae
3Anemia in IBD: Algorithm
Anemia affects 30–75% of IBD patients—more prevalent than any extraintestinal manifestation. Causes: iron deficiency (most common), anemia of chronic disease (inflammation blocks iron utilization via hepcidin), B12/folate deficiency, bone marrow suppression from thiopurines, hemolysis (rare, sulfasalazine). Workup: CBC with reticulocyte count, ferritin, TSAT, CRP, B12, folate, LDH, haptoglobin, Coombs if hemolysis suspected. ECCO 2015 anemia guideline: target Hb in female ≥12, male ≥13; IV iron first-line if moderate–severe anemia (Hb <10), active disease, prior oral intolerance, or need for quick correction (pre-surgery); oral iron reserved for mild anemia with quiescent disease. Dose calculation (Ganzoni formula): iron deficit (mg) = weight (kg) × (target Hb − actual Hb) × 2.4 + 500 (stores). Practical: ferric carboxymaltose 1000 mg (max 20 mg/kg) as single infusion covers most deficits. Monitor response at 4–12 weeks. Transfusion: reserve for symptomatic anemia Hb <7 or <8 with cardiopulmonary disease. Erythropoietin: consider if persistent anemia despite iron repletion and ongoing inflammation (200 IU/kg thrice weekly).
Don't over-investigate iron deficiency in IBD—it's almost always blood loss plus impaired absorption. Treat empirically; investigate further only if atypical (e.g., male with no GI bleeding history).
- Anemia in 30–75% of IBD patients
- IV iron first-line if Hb <10 or active disease
- Ferric carboxymaltose 1000 mg single infusion
- Monitor response at 4–12 weeks
- Target Hb ≥12 (F), ≥13 (M)
4Special Nutritional Scenarios: Short Bowel, Stricture, Fistula
Short bowel syndrome (SBS) after extensive Crohn's resection: residual bowel <200 cm, jejunostomy or end ileostomy, high-output stoma (>1.5 L/day). Three phases: (1) hypersecretory/acute (first weeks—IV fluids, PPI, loperamide 4–16 mg/day, codeine if needed); (2) adaptation (weeks–months—gradual enteral feeding, hypotonic fluids restricted to <500 mL/day, oral rehydration solution preferred); (3) maintenance (months–years—optimize oral intake, home parenteral nutrition if persistent deficits). Teduglutide (GLP-2 analog) reduces PN dependence—consider in stable SBS with residual bowel ≥60 cm. Stricturing disease: low-residue/low-fiber diet during obstructive symptoms; once strictures fibrotic (not actively inflammatory), endoscopic dilation or surgical stricturoplasty with normal diet resumed. Fistulae: high output enterocutaneous fistulae may require bowel rest, TPN, octreotide; enteral nutrition tolerated if distal to fistula. EEN is particularly useful in perianal fistulizing Crohn's and pre-operative optimization. Ostomy nutrition: hydration priority (electrolyte-rich fluids 1.5–2 L, limit plain water which worsens output); avoid high-fiber raw vegetables early; monitor magnesium (common deficiency in jejunostomies). Saudi pilgrimage considerations: proactive ostomy supply planning and stoma nurse contact for Hajj/Umrah travelers.
High-output ostomy patients should drink electrolyte solution, not water. Plain water paradoxically increases output (osmotic gradient draws sodium into bowel).
- SBS three phases: hypersecretory, adaptation, maintenance
- Teduglutide for stable SBS reducing PN dependence
- Stricture = low-residue diet during obstruction
- Ostomy hydration = electrolyte solution, not water
- Pre-Hajj ostomy planning for Saudi patients
- Malnutrition affects 20–85%; screen every visit with MUST
- Sarcopenia = independent predictor of biologic failure and surgical complications
- Iron deficiency in 45%—IV iron first-line if active disease or Hb <10
- Vitamin D deficiency highly prevalent in Saudi IBD—screen and treat aggressively
Dietary Therapies: EEN, CD-TREAT, CDED & Mediterranean Diet
Evidence-based dietary interventions for IBD with practical implementation protocols and adaptation to Saudi food culture.
1Exclusive Enteral Nutrition (EEN): The Evidence
EEN = 100% of calories from a nutritionally complete liquid formula (polymeric, semi-elemental, or elemental) for 6–8 weeks. First-line therapy for active pediatric Crohn's in Europe (ECCO/ESPGHAN 2020)—remission rates 60–85% comparable to corticosteroids, with superior mucosal healing (33% vs 13%) and growth benefits, without steroid toxicity. Meta-analyses in adults show lower efficacy (~45% remission) but consistent benefit when adherent. Mechanisms: alteration of microbiome (reduces Faecalibacterium, Proteobacteria), reduced antigen exposure, anti-inflammatory effects of specific fatty acids and nutrients. Formulas: polymeric (whole protein, e.g., Modulen IBD, Nutricia) best tolerated and similar efficacy to elemental; ~1500–2000 kcal/day based on individual needs. Implementation: gradual transition over 3–5 days; allow clear fluids and water ad libitum; usually oral but NG tube if palatability poor; maintain for 6–8 weeks before food reintroduction. Adherence is the main challenge in adults—pediatric units use NG overnight feeds for schooling support. Post-EEN: structured food reintroduction (one food group per 2–3 days) or transition to CDED (see next section). Saudi context: Nutricia and Abbott formulas available; culturally, dates water, laban are often mistakenly added—emphasize exclusivity; Ramadan fasting complicates adherence—plan around.
EEN is underused in adult Crohn's because clinicians assume adherence failure. Offer it to motivated patients, especially those refusing biologics or corticosteroids, and use dietitian support for palatability strategies.
- First-line for pediatric Crohn's (ECCO/ESPGHAN)
- 60–85% remission, superior mucosal healing vs steroids in children
- Polymeric formulas tolerated equivalently to elemental
- 6–8 weeks duration, then structured reintroduction
- Saudi adaptation: Ramadan planning, cultural food exclusions
2CDED & CD-TREAT: Food-Based Protocols
Crohn's Disease Exclusion Diet (CDED): developed by Levine and colleagues to replicate EEN effects with real food plus partial enteral nutrition (PEN). Three phases over 24 weeks: Phase 1 (weeks 1–6, 50% PEN + mandatory foods [chicken breast, eggs, potatoes, bananas, apples, rice] + disallowed foods [gluten, dairy, emulsifiers, processed meats, most fats]); Phase 2 (weeks 7–12, 25% PEN, gradual introduction of additional allowed foods); Phase 3 (maintenance, 25% PEN with expanded diet). The Lancet 2019 trial (Levine et al): CDED+PEN 75% vs EEN 59% clinical remission at week 6 in pediatric Crohn's—comparable efficacy with far better tolerability (97% vs 73% adherence). Adult trial (CDED-AD): 44% sustained remission at week 24. CD-TREAT (Svolos 2019): ordinary-food diet mimicking EEN composition; induces similar microbiome changes; small open-label evidence. SCD (Specific Carbohydrate Diet): excludes disaccharides and most starches; DINE-CD trial showed equivalence to Mediterranean diet but no superiority. Clinical implementation: dietitian-led; stepwise introduction; requires motivation and family support; effective when adherent. Saudi adaptation: most CDED foods (rice, chicken, eggs, potatoes, fruits) are staples in Saudi diet, making implementation feasible; dates need moderation in Phase 1; challenge comes from social gatherings (kabsa, mandi rich in forbidden ingredients)—provide family-oriented counseling.
CDED has changed adult Crohn's practice because it works with real food and rewards gradual liberalization. Most Saudi patients accept it once they see the halal-friendly food list.
- CDED = PEN + structured real-food exclusion (gluten, dairy, emulsifiers)
- Lancet 2019: CDED 75% vs EEN 59% pediatric remission
- Adult trial (CDED-AD): 44% sustained remission
- SCD = DINE-CD equivalent to Mediterranean—no superiority
- Saudi staples align well with CDED allowed foods
3Mediterranean Diet & UC-Specific Approaches
Mediterranean diet (high fruit/vegetables/olive oil/fish, moderate dairy, low red meat/processed foods) is increasingly supported for IBD. DINE-CD (Lewis 2021, Crohn's): Mediterranean vs SCD showed equivalence for symptom remission at 6 weeks (46.5% vs 43.5%)—Mediterranean won on simplicity and sustainability. For UC: UC-SCD and Mediterranean both show symptom benefit; dietary therapy more useful as adjunct than primary induction in UC. Emerging protocols: IBD-AID (anti-inflammatory diet, UMass approach), low-FODMAP for functional symptoms in quiescent IBD (NOT for active disease—may worsen bifidobacteria), autoimmune protocol (AIP, limited evidence). Key principles: avoid ultraprocessed foods and emulsifiers (carboxymethylcellulose, polysorbate-80—animal data show mucus barrier disruption), minimize artificial sweeteners, emphasize whole foods and diverse plant fiber (in remission), adequate protein and omega-3. Foods to limit in active disease: raw high-fiber vegetables (mechanical obstruction risk in strictures), lactose (transient intolerance common), spicy foods, high-fat fried foods, alcohol. Saudi context: traditional diet is close to Mediterranean in fish (Red Sea), olive oil (though variable in Saudi cuisine), and legumes, but high in processed carbohydrates, fried foods, and sugar-sweetened beverages—reframe dietary counseling around familiar foods rather than imposing foreign diets.
Emulsifiers in ultraprocessed foods (ice cream, salad dressings, packaged baked goods) disrupt intestinal mucus barrier in animal models. Pragmatic message: minimize ultraprocessed, maximize whole foods.
- DINE-CD: Mediterranean ≈ SCD at 6 weeks; choose Mediterranean for sustainability
- Avoid ultraprocessed foods and emulsifiers
- Low-FODMAP OK for functional symptoms in REMISSION only
- Saudi traditional diet partially aligned; target processed foods
- Adjunct to medical therapy in UC, not primary induction
4Implementation: Dietitian Pathways & Adherence Strategies
A successful dietary therapy program requires: (1) dedicated IBD-trained dietitian embedded in clinic; (2) structured consultation time (initial 60 min, follow-up 30 min); (3) patient-centered goal setting; (4) written meal plans adapted to cultural context; (5) regular follow-up (weekly initially, then biweekly); (6) outcome tracking (symptom score, biomarkers, weight, adherence). Adherence barriers: social pressure (family meals, eating out), cost (specialized formulas), palatability (EEN), cultural expectations, travel (Hajj, Umrah), fasting (Ramadan). Strategies: family education sessions (bring a family member to appointments), batch cooking workshops, apps for tracking (MyIBD, CDED app), WhatsApp peer groups with dietitian moderation, phone counseling for flare-ups. Saudi-specific: SGA's patient education materials in Arabic, dietitian directory via MOH, partnership with major centers (KFSHRC, KFMC, KAUH) for shared care; Ramadan-specific protocols (shift PEN/EEN to Iftar-Suhoor windows, medical exemption with patient's religious authority if needed); pilgrimage pre-departure consultation to plan hydration, stoma care, medication. Outcomes to track: CRP, fecal calprotectin, Hb/ferritin, weight, symptom score (PRO-2 or equivalent), quality of life (IBDQ-32), adherence percentage. Publish your program—QI projects on dietary therapy are underrepresented in Saudi literature.
Embedding a dietitian in IBD clinic boosts dietary therapy adoption by >3x compared to external referral. Make this your unit's first QI project if you don't have one.
- Dedicated IBD dietitian + structured consultations + cultural adaptation
- Family sessions improve adherence in Saudi context
- Ramadan/Hajj-specific protocols essential
- Track CRP, calprotectin, IBDQ-32, adherence %
- Publish dietary therapy QI — underrepresented in Saudi literature
- EEN = first-line pediatric Crohn's induction; underused in adults
- CDED+PEN = effective, tolerable alternative in pediatric and adult Crohn's
- Mediterranean = sustainable maintenance diet
- Embedded dietitian + Saudi cultural adaptation = success
Psychology in IBD: Screening & Integrated Care
Mental health co-morbidity screening, brain-gut axis, evidence-based interventions, and Saudi-context delivery.
1Prevalence & Bidirectional Brain-Gut Axis
Anxiety affects 35% of IBD patients (vs 17% general population); depression affects 25% (vs 6%); rates rise to >60% during active disease. The brain-gut axis is bidirectional: (1) inflammation drives psychological symptoms via cytokines (TNF, IL-6, IL-1β cross blood-brain barrier, alter neurotransmitter balance, activate microglia); (2) psychological stress worsens IBD via HPA axis activation, sympathetic drive, altered microbiome, impaired epithelial barrier—Mawdsley & Rampton showed CD patients with perceived stress double relapse risk at 18 months; (3) common pathophysiology (vagal tone, microbiome metabolites like SCFAs, serotonin metabolism). Fatigue affects 50% even in clinical remission—multifactorial (anemia, sleep disturbance, depression, subclinical inflammation, medications). Functional overlap: 30–50% of IBD patients in remission still have IBS-like symptoms (post-inflammatory visceral hypersensitivity). Suicidal ideation: elevated risk in active IBD, corticosteroid use, surgery (especially ostomy), and young patients—always screen. Saudi context: mental health stigma historically limits disclosure; cultural idioms of distress (somatization of psychological symptoms, "qalb taab" — "tired heart"); gender differences in help-seeking; religious framework as both resource and barrier—acknowledge spiritual context respectfully and work within it.
When a stable UC patient reports worsening symptoms with normal calprotectin and endoscopy, always screen for anxiety, depression, and IBS overlap—treatment is cognitive/behavioral, not escalation of biologics.
- Anxiety 35%, depression 25% baseline; >60% in flare
- Brain-gut axis bidirectional: inflammation ↔ psychological symptoms
- Stress doubles relapse risk in CD (Mawdsley/Rampton)
- Fatigue in 50% even in remission—multifactorial
- Saudi cultural context: stigma, somatization, religious framework
2Screening Tools: PHQ-9, GAD-7, IBD-F, Nightingale
Standardized screening at baseline and annually (or at major clinical changes): (1) PHQ-9 (Patient Health Questionnaire-9) for depression—9 items, validated Arabic version (PHQ-9-Ar), scored 0–27; ≥10 moderate, ≥15 severe; item 9 asks about suicidal ideation and mandates response if positive; (2) GAD-7 (Generalized Anxiety Disorder-7) for anxiety—7 items, Arabic validated, 0–21; ≥10 moderate, ≥15 severe; (3) IBD-F (IBD-Fatigue Scale)—disease-specific, 4 items core; use to quantify and track; (4) IBDQ-32 (IBD Questionnaire) for quality of life—bowel, systemic, emotional, social subscales; (5) Brief Illness Perception Questionnaire (B-IPQ) for illness perceptions that predict adherence; (6) specialized (if flagged): Columbia Suicide Severity Rating Scale (C-SSRS) when PHQ-9 item 9 positive. Implementation: tablet-based pre-visit questionnaires; automatic alert to physician for scores ≥10; dedicated psychology/psychiatry referral pathway. Saudi-adapted workflow: offer both Arabic and English; ensure confidentiality (family often present—request private time with patient); non-judgmental normalizing language ("this is part of standard IBD care, not a reflection on you"). Document baseline scores; track trajectory; target interventions for scores ≥10.
The most important screening question you can ask is "In the past 2 weeks, have you had thoughts of self-harm?" — from PHQ-9 item 9. Answer ≥1 mandates same-day safety assessment.
- PHQ-9 (depression), GAD-7 (anxiety) — validated Arabic versions
- IBD-F for disease-specific fatigue
- IBDQ-32 for quality of life
- Score ≥10 = moderate, refer or treat
- PHQ-9 item 9 positive = same-day safety assessment
3Evidence-Based Psychological Interventions
CBT (Cognitive Behavioral Therapy): Strongest evidence for IBD. Mikocka-Walus 2022 systematic review of 14 RCTs: CBT reduces anxiety and depression, improves quality of life; disease-specific CBT (addressing illness cognitions, adherence, symptom management) outperforms generic CBT. Typical protocol: 6–10 sessions, 50 minutes each, individual or group; face-to-face, online, or self-help via workbook. Gut-directed hypnotherapy: Keefer and colleagues demonstrated benefit for UC remission maintenance (41% vs 12% relapse at 12 months in UC patients receiving 7 sessions of hypnotherapy)—mechanisms likely via anti-inflammatory effects and stress reduction. Mindfulness-based interventions: Schoultz 2015 RCT showed MBCT reduced IBD stress and improved quality of life. Third-wave therapies (ACT—Acceptance and Commitment Therapy): emerging evidence in IBD. Pharmacotherapy: consider antidepressants if CBT unavailable, refused, or insufficient—SSRIs generally safe in IBD (sertraline, escitalopram); tricyclics (amitriptyline 10–50 mg) can address overlapping IBS/visceral pain plus depression; avoid bupropion in active disease (seizure risk slightly elevated). Low-dose naltrexone (4.5 mg): preliminary evidence for mild CD activity and fatigue; mechanism unclear. Integration: embed psychologist in IBD clinic, step-care model (self-help → guided self-help → structured CBT → specialist), telehealth expands reach. Saudi context: Saudi Ministry of Health mental health initiatives, telemedicine growth, Arabic CBT workbooks emerging (King Abdulaziz University Hospital, Riyadh programs).
Gut-directed hypnotherapy has remarkable UC maintenance data—seven sessions cut 12-month relapse from 12% to 41% improvement. It's safe, training is accessible, and pairs well with biologics.
- CBT = strongest evidence; 6–10 sessions, disease-specific > generic
- Gut-directed hypnotherapy maintains UC remission
- Mindfulness reduces stress, improves QoL
- SSRIs safe; amitriptyline for IBS overlap
- Step-care model + telehealth for Saudi access
4Fatigue, Sleep & Sexual Health
Fatigue deserves dedicated attention. Workup: rule out anemia, thyroid disease, vitamin D/B12 deficiency, subclinical inflammation (CRP, calprotectin), medications (sulfasalazine, methotrexate, steroids), sleep disorder (screen with ISI—Insomnia Severity Index, STOP-BANG for OSA), depression. Interventions: treat reversible causes; structured exercise prescription (3 sessions/week moderate intensity improves fatigue per Ibarra 2017); CBT for fatigue (I-CARE trial); modafinil has case-series evidence only—not first-line. Sleep: 50–70% of IBD patients report poor sleep; active disease and steroids worsen it; sleep disorders also worsen IBD trajectory (inflammation follows sleep deprivation). Intervention: sleep hygiene, CBT-I (CBT for insomnia—gold standard, can be delivered digitally), melatonin 3–5 mg for transient use, avoid benzodiazepines. Sexual health often ignored: 50% of IBD patients report sexual dysfunction (body image with ostomy, perianal disease, fistulae, medications like SSRIs, fatigue, depression). Ask directly using a simple opener ("Many IBD patients have concerns about sexual health—has this affected you?"); refer to specialized counseling, urology/gynecology for anatomical issues. Saudi cultural sensitivity: discuss with patient alone; gender-matched counseling preferred when possible; culturally sensitive language avoiding crude terms; involve spouse when appropriate and consented.
If a patient has fatigue in biochemical remission, think sleep. Most IBD fatigue is actually insomnia-driven or depression-driven. CBT-I or CBT-fatigue trumps modafinil.
- Fatigue workup: anemia, thyroid, inflammation, sleep, depression
- Exercise + CBT-fatigue > pharmacotherapy
- Sleep: 50–70% impaired; CBT-I gold standard
- Sexual dysfunction in 50%—ask directly, refer appropriately
- Saudi: gender-matched counseling; private time with patient
- Anxiety/depression in 25–35% baseline, >60% during flare
- Screen with PHQ-9/GAD-7 (Arabic validated) annually
- CBT = strongest evidence; hypnotherapy = UC maintenance
- Fatigue, sleep, sexual health = ask directly, treat systematically
Shared Decision-Making & Communication Skills
Decision aids, motivational interviewing, breaking bad news, and vaccination/family-planning counseling — practiced in Saudi cultural context.
1SDM Frameworks & Decision Aids
Shared Decision-Making (SDM) = clinician and patient jointly arrive at a treatment decision using best evidence and patient values. Three-talk model (Elwyn 2012): (1) Team talk ("We have a decision to make together"), (2) Option talk (present options with benefits/harms), (3) Decision talk (elicit values, arrive at decision). SDM is ethically required, legally protected (informed consent), and improves adherence, satisfaction, and outcomes. Barriers: time, clinician confidence, patient literacy, cultural expectations of physician authority (especially in Saudi Arabia and Gulf region where some patients prefer deferential decision-making). IBD decision aids: Crohn's Treatment Decision Aid (CCFA), UC Treatment Decision Aid (AGA/CCFA), Mayo Clinic IBD Decision Aids, Option Grid for biologics—all present side-by-side comparison of therapies. Key IBD decisions requiring SDM: (1) biologic vs small molecule choice; (2) top-down vs step-up; (3) combo therapy vs mono therapy; (4) surgery vs escalation; (5) ostomy vs IPAA; (6) surveillance colonoscopy frequency; (7) pregnancy planning. Saudi adaptation: recognize family involvement is culturally appropriate (ask patient: "Would you like family members present?"); frame shared decisions in ways compatible with consultative norms; written decision aids in Arabic (SGA materials); bilingual delivery; allow time for family discussion before finalization.
Saudi patients don't reject SDM — they contextualize it. Frame the options, provide recommendations, but honor the family's role in deliberation. Offer a separate follow-up visit to finalize.
- Three-talk model: team → option → decision
- Validated IBD decision aids (CCFA, AGA, Option Grid)
- Seven common IBD SDM decisions
- Saudi: involve family respectfully, bilingual materials
- Offer follow-up for deliberation when stakes are high
2Motivational Interviewing for Adherence & Lifestyle
Motivational Interviewing (MI): patient-centered counseling style to strengthen intrinsic motivation for change. Core principles (OARS): Open questions, Affirmations, Reflective listening, Summaries. Four processes: engaging, focusing, evoking, planning. Apply to IBD for: medication adherence (biologic self-injection reluctance, injection fatigue), smoking cessation (Crohn's—smoking cessation is the single most impactful modifiable intervention, halves flare risk and post-operative recurrence), dietary changes, exercise adoption, substance use, cannabis counseling (emerging issue—some patients use for symptom relief despite limited evidence). Techniques: elicit-provide-elicit ("What do you know about this medication? [Provide information] What do you think?"), rolling with resistance, exploring ambivalence, importance/confidence rulers ("On a scale of 0–10, how important is quitting smoking to you? Why not lower?"). Specific IBD applications: (1) biologic hesitancy—explore underlying fears (injections, side effects, long-term safety, cost), provide information, work with the patient's values; (2) smoking cessation in Crohn's—non-judgmental approach, connect to disease outcomes, pharmacotherapy (varenicline, NRT) + behavioral support; (3) cannabis use—acknowledge symptom benefit patients perceive, discuss lack of disease-modifying effect and potential worsening of symptoms, explore motivation; (4) exercise—start small (10-minute walks), build gradually. Saudi context: smoking prevalence (~20% males, <5% females, increasing); shisha (waterpipe) use common and underestimated for nicotine load; vaping rising; legal cannabis unavailable but patients may travel/import.
Shisha is often framed as "safer than cigarettes" by patients — but it delivers higher nicotine and CO exposure per session, and is a major driver of Crohn's flares in Gulf patients. Address it explicitly.
- OARS + four processes = MI core
- Smoking cessation = most impactful Crohn's intervention
- Importance/confidence rulers operationalize ambivalence
- Shisha is major Crohn's flare driver — address explicitly
- Cannabis: acknowledge symptom relief, highlight lack of disease modification
3Breaking Bad News, Vaccination & Family Planning Counseling
Breaking bad news (SPIKES protocol, Baile 2000): Setting, Perception, Invitation, Knowledge, Empathy, Strategy. Apply to IBD for: new diagnosis (especially pediatric), dysplasia/cancer findings, treatment failure, need for surgery, colostomy conversion, PSC diagnosis, infertility from prior IPAA. Key points: private setting, sit down, warn shot ("I have some difficult news"), pace information, allow silence, acknowledge emotion before giving more data, end with clear next step and follow-up. Saudi cultural specifics: family often strongly prefer to receive news before patient—explicit negotiation at outset ("Some patients prefer to hear their results first, others prefer family to be told together or first—what do you prefer?"); religious framing may be comforting (allow patient to lead); avoid definitive prognostic statements in terminal scenarios when family requests protection. Vaccination counseling: high rates of vaccine hesitancy in chronic disease populations; proactive schedule (see Month 2 content); use strong normalization ("This is the standard of care for all our IBD patients"); address halal concerns for porcine-derived vaccines (rotavirus is primary issue—most are halal-certified or accepted per major fatwa councils; document consent). Family planning: see Month 9 for pregnancy content; key here is communication—use visuals for medication safety (PIANO data graphics), discuss fertility impact of surgery before IPAA, involve partner when consented. Contraception: IBD does not change most contraceptive recommendations; COCs OK unless severe disease with VTE risk; progestin-only preferred in active disease or VTE history; IUDs fine. Sulfasalazine causes reversible oligospermia—counsel men considering paternity.
When breaking bad news in Saudi Arabia, always negotiate who receives information first. A blanket "patient first" policy is not culturally calibrated. A single early question ("Who would you like to be told, and in what order?") prevents distress.
- SPIKES protocol for bad news — universal but culturally adapted
- Saudi: negotiate disclosure order upfront with patient
- Vaccine hesitancy → normalize as standard IBD care, address halal concerns
- Contraception: most methods fine; progestin-only if VTE risk
- Sulfasalazine oligospermia — counsel males planning paternity
- SDM three-talk model + validated IBD decision aids
- MI for adherence, smoking cessation (including shisha), lifestyle
- SPIKES for bad news + Saudi disclosure negotiation
- Halal vaccine concerns addressable; contraception mostly unchanged
Patient Panel: Living with IBD
Facilitated dialogue with IBD patients sharing care experience, unmet needs, and advocacy perspectives.
1Panel Format & Facilitation
Objective: fellows hear directly from patients about the lived experience of IBD, strengths and gaps in current care, and priorities for improvement. Structure: 4–6 patients representing diversity (gender, age, disease duration, phenotype, surgical vs medical, ostomy, pediatric-to-adult transition, pregnancy experience, remote/rural access); 30 min patient narratives, 45 min facilitated Q&A, 15 min debrief without patients. Recruitment via IBD clinic, SGA patient liaison, social media IBD communities, and support groups. Consent and briefing essential—patients may share sensitive details; ground rules on confidentiality ("what's said in this room stays in this room"); optional anonymity (first names only, no photos). Facilitator role: create safe space, invite quieter voices, redirect from "horror story" competition to constructive insights, ensure all fellows engage. Sample questions: "What did we get right and wrong at your diagnosis?", "What do you wish we understood about flares?", "How has IBD affected relationships, work, faith?", "What would make the biggest difference?" Saudi-specific topics: navigating flares during Hajj, family dynamics in decision-making, workplace accommodations in Saudi public/private sectors, access to psychological support, cultural stigma around ostomy, stigma around infertility from IPAA, experience of male vs female patients with gender-matched care.
The moment a fellow realizes they've been treating a disease rather than a person — that's the transformative outcome of a patient panel. It cannot be achieved through lectures.
- 4–6 patients with diversity of experience
- Ground rules on confidentiality and anonymity
- Facilitator keeps dialogue constructive
- Saudi-specific topics: Hajj, family, workplace, gender
- 15 min debrief without patients = essential reflection
2Common Themes: Diagnosis Delay, Communication, Stigma
Consistent feedback across IBD patient surveys globally: (1) diagnostic delay (Saudi data: median 11 months for CD, 6 months for UC—often initially misdiagnosed as IBS, infection, or psychosomatic); (2) poor communication at diagnosis (jargon, no written information, rushed discussion, no follow-up in 1–2 weeks to digest); (3) inadequate psychological support; (4) financial stress (medications, time off work, transport to tertiary center); (5) stigma (ostomy, gastrointestinal symptoms, chronic illness); (6) lack of coordinated care across specialties (GI, surgery, rheumatology, dermatology, ophthalmology, dietitian); (7) transition from pediatric to adult care experienced as abrupt and disruptive; (8) pregnancy—conflicting advice from GI and obstetrics, anxiety about medications. Saudi-specific patterns: (a) extensive "doctor shopping" before reaching IBD specialist due to tertiary care concentration in Riyadh/Jeddah; (b) traditional remedies (za'atar, black seed, camel milk, Hijama [cupping]) tried before or alongside medical therapy—non-judgmental acknowledgment while not endorsing; (c) fasting during Ramadan—patients often stop medications to avoid "breaking" fast; proactive counseling needed that medications continue; (d) Hajj/Umrah as priority—patients will travel despite active disease and need preparation; (e) gender-matched providers matter to many female patients—respect preference and facilitate when possible; (f) family-centered decision-making—clinicians accustomed to Western individualism must adapt.
Patients remember communication quality more than clinical accuracy. A 30-second acknowledgment of emotion, a written summary at the end of visit, and a "What questions do you have?" are higher-impact interventions than most biologic switches.
- Saudi diagnostic delay: 11 mo CD, 6 mo UC
- Common gaps: communication, psychology, coordination, transition
- Traditional remedies: acknowledge respectfully, don't endorse
- Ramadan medication continuation needs proactive counseling
- Family-centered care is culturally normative
3Patient Advocacy & Self-Management
Patient advocacy organizations globally: Crohn's & Colitis Foundation (US), Crohn's & Colitis UK, European Federation of Crohn's and UC Associations (EFCCA), Korean Association of CC, Australian CCCA. Saudi Arabia: SGA patient education resources (Arabic), Crohn's & Colitis Saudi Arabia (emerging patient group, social media-based), regional support through social media (Facebook, WhatsApp groups, Instagram) are culturally prominent. Self-management competencies: (1) medication management (names, doses, purposes, side effects to watch); (2) symptom tracking (apps like MyIBD, paper diaries, symptom thermometers); (3) flare recognition (when to call vs go to ED vs wait); (4) vaccination tracking; (5) diet journaling; (6) pre-travel preparation (Hajj/Umrah specifically); (7) navigating work/school; (8) building family understanding; (9) emergency plan (contact list, ED go-bag, medication list). Tools: IBD passport (CCFA-style booklet), shared care record, patient-held portion of EMR, SGA app for medication reminders and appointments. Peer support: buddy programs, online peer groups, local meet-ups (coffee in Riyadh, majlis-style gatherings). Resilience factors: social support, sense of purpose, realistic hope, spirituality (very important in Saudi context), sense of control over decisions. Final message to panelists and fellows: the fellow-patient relationship is a partnership; both parties bring expertise—the clinician on disease, the patient on living with it.
Patients who feel like partners adhere more, flare less, and have better quality of life—regardless of disease severity. Make partnership your default posture.
- Saudi advocacy: SGA, emerging CC-SA, social media groups
- Self-management: meds, symptoms, flares, vaccines, travel, work
- Resilience: social support, purpose, spirituality (important in KSA)
- Peer support in majlis-style gatherings culturally resonant
- Partnership = adherence + QoL, independent of severity
4Fellow Reflection & Commitment
Close with structured fellow reflection (15 minutes post-panel, without patients). Prompts: (1) What surprised you most? (2) What did a patient say that you want to remember? (3) What gap in your own practice did this highlight? (4) What is one concrete change you will make in your next clinic? (5) What is one systemic gap you want to advocate for? Written reflection in portfolio (one page, reviewed with program director). Commitments tracked: e.g., "I will offer a written summary at every new diagnosis visit"; "I will screen for anxiety/depression on every annual review"; "I will proactively ask about Hajj/Umrah plans yearly"; "I will join the SGA patient education committee." Accountability: share commitments with co-fellows; revisit at mid-year and end-of-year reviews. Also introduce concept of trainee-patient partnership for research: IBD patient advisory board for registry design, trial protocols, outcome measures (PROs). SGA model: trainees participate in or lead one patient-engaged project during fellowship year. Final message: training produces competent clinicians; working alongside patients produces transformative ones.
Write down your three commitments from today. Post them in your clinic. Review them in six months. This is how panels become practice.
- 15-min structured reflection after panel
- 5 prompts + 3 concrete commitments written down
- Accountability at mid-year and end-of-year reviews
- Patient advisory board for research/QI projects
- Training = competent; partnership = transformative
- Patient panel = transformative learning not achievable through lectures
- Diagnostic delay and communication gaps are fixable Saudi priorities
- Ramadan/Hajj proactive counseling = culturally essential
- Partnership with patients produces transformative clinicians
Assessment
Counseling skills OSCE (3 stations) + Nutritional care plan + Reflective essay
Clinical Pearls
EEN achieves remission in 60-80% of pediatric CD — first-line in children, underused in adults
Iron deficiency in >30% of IBD patients — IV iron preferred when Hb <10 g/dL
Screen ALL IBD patients for anxiety (GAD-7) and depression (PHQ-9) annually
Fatigue affects >50% even in remission — multifactorial: anemia, sleep, psychology, disease, medications
Practice Points
Implement MUST screening at every IBD clinic visit — takes <2 minutes
Develop a dietitian referral pathway for your IBD clinic
Screen for B12 deficiency in ALL patients with ileal disease or prior ileal resection
Key References
Forbes A, et al. ESPEN guideline: Clinical nutrition in IBD. Clin Nutr. 2017;36:321-347
Levine A, et al. CDED plus partial EN for CD remission. Lancet. 2019;394:420-429
Mikocka-Walus A, et al. CBT for IBD: systematic review. J Crohns Colitis. 2022;16:147-162
Reading List
ESPEN Guideline on Clinical Nutrition in IBD
Forbes A, et al. — Clin Nutr (2017)
EEN for CD — mechanism and evidence
Sigall Boneh R, et al. — Clin Gastroenterol Hepatol (2021)
CDED plus partial EN — Lancet trial
Levine A, et al. — Lancet (2019)
Psychosocial aspects of IBD — AGA Position
Regueiro M, et al. — Gastroenterology (2019)